JP2010500370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500370A5 JP2010500370A5 JP2009523966A JP2009523966A JP2010500370A5 JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5 JP 2009523966 A JP2009523966 A JP 2009523966A JP 2009523966 A JP2009523966 A JP 2009523966A JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- huluc63
- ebmt
- administration induces
- remission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229960004137 elotuzumab Drugs 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83625006P | 2006-08-07 | 2006-08-07 | |
| US85614406P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/075401 WO2008019376A2 (en) | 2006-08-07 | 2007-08-07 | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Division JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010500370A JP2010500370A (ja) | 2010-01-07 |
| JP2010500370A5 true JP2010500370A5 (enExample) | 2010-09-30 |
Family
ID=39033619
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523966A Withdrawn JP2010500370A (ja) | 2006-08-07 | 2007-08-07 | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7842293B2 (enExample) |
| EP (2) | EP2068930B1 (enExample) |
| JP (4) | JP2010500370A (enExample) |
| AU (1) | AU2007281682B2 (enExample) |
| BR (1) | BRPI0716475A2 (enExample) |
| CA (1) | CA2660102C (enExample) |
| CY (1) | CY1113309T1 (enExample) |
| DK (1) | DK2068930T3 (enExample) |
| ES (1) | ES2391790T3 (enExample) |
| HR (1) | HRP20120934T1 (enExample) |
| IL (1) | IL196920A (enExample) |
| MX (1) | MX2009001440A (enExample) |
| NO (1) | NO345083B1 (enExample) |
| NZ (1) | NZ574979A (enExample) |
| PL (1) | PL2068930T3 (enExample) |
| PT (1) | PT2068930E (enExample) |
| WO (1) | WO2008019376A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2641601T (pt) * | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
| MX2009001440A (es) * | 2006-08-07 | 2009-04-15 | Pdl Biopharma Inc | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. |
| US9096681B2 (en) * | 2008-06-02 | 2015-08-04 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides |
| EP2361263A1 (en) | 2008-10-31 | 2011-08-31 | Abbott Biotherapeutics Corp. | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| AU2011382454B2 (en) | 2011-11-30 | 2017-02-23 | Abbvie Biotechnology Ltd | Vectors and host cells comprising a modified SV40 promoter for protein expression |
| KR102427777B1 (ko) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| AU2015339012B2 (en) * | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| EA201791049A1 (ru) | 2014-12-04 | 2017-10-31 | Бристол-Майерс Сквибб Компани | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) |
| CN107949425A (zh) | 2015-06-29 | 2018-04-20 | 百时美施贵宝公司 | 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| CA2220971A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| MX2009001440A (es) * | 2006-08-07 | 2009-04-15 | Pdl Biopharma Inc | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. |
| PT2641601T (pt) * | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
-
2007
- 2007-08-07 MX MX2009001440A patent/MX2009001440A/es active IP Right Grant
- 2007-08-07 NZ NZ574979A patent/NZ574979A/en unknown
- 2007-08-07 EP EP07840744A patent/EP2068930B1/en active Active
- 2007-08-07 PL PL07840744T patent/PL2068930T3/pl unknown
- 2007-08-07 WO PCT/US2007/075401 patent/WO2008019376A2/en not_active Ceased
- 2007-08-07 BR BRPI0716475A patent/BRPI0716475A2/pt not_active Application Discontinuation
- 2007-08-07 DK DK07840744.2T patent/DK2068930T3/da active
- 2007-08-07 PT PT07840744T patent/PT2068930E/pt unknown
- 2007-08-07 HR HRP20120934TT patent/HRP20120934T1/hr unknown
- 2007-08-07 ES ES07840744T patent/ES2391790T3/es active Active
- 2007-08-07 AU AU2007281682A patent/AU2007281682B2/en active Active
- 2007-08-07 CA CA2660102A patent/CA2660102C/en active Active
- 2007-08-07 JP JP2009523966A patent/JP2010500370A/ja not_active Withdrawn
- 2007-08-07 EP EP11176209A patent/EP2425849A3/en not_active Withdrawn
- 2007-08-07 US US11/835,245 patent/US7842293B2/en active Active
-
2009
- 2009-02-05 IL IL196920A patent/IL196920A/en active Protection Beyond IP Right Term
- 2009-03-03 NO NO20090969A patent/NO345083B1/no unknown
-
2010
- 2010-10-12 US US12/903,051 patent/US20110165154A1/en not_active Abandoned
-
2012
- 2012-10-31 CY CY20121101037T patent/CY1113309T1/el unknown
-
2013
- 2013-08-30 JP JP2013178996A patent/JP5775125B2/ja active Active
-
2015
- 2015-04-01 JP JP2015074786A patent/JP6005205B2/ja active Active
-
2016
- 2016-04-06 US US15/091,977 patent/US20160206734A1/en not_active Abandoned
- 2016-09-05 JP JP2016172453A patent/JP2017025077A/ja active Pending